The Silent Threat of West Africa: A Comprehensive Guide to Lassa Virus

Lassa Virus: Symptoms, Spread, and Treatment

While global health headlines are often dominated by Ebola or pandemic influenza, a persistent and deadly threat continues to affect hundreds of thousands of people across West Africa every year: the Lassa virus (LASV). Causing Lassa Fever, this viral hemorrhagic disease is endemic in countries like Nigeria, Liberia, Sierra Leone, and Guinea.

First identified in 1969 in the town of Lassa, Nigeria, after two missionary nurses died from the infection, the virus has since become a major public health priority. Because it shares many symptoms with common tropical diseases like malaria, it is often referred to as a “silent” killer, as many cases go undiagnosed until it is too late.

In this extensive guide, we will explore the biology of the Lassa virus, its unique transmission through rodent vectors, the devastating neurological impacts it can have, and the current landscape of medical treatment and vaccine research.

What is the Lassa Virus? Understanding the Arenavirus Family

Lassa virus is an enveloped, single-stranded, bisegmented RNA virus. It belongs to the family Arenaviridae. Under an electron microscope, the virus has a grainy appearance due to the presence of ribosomes acquired from its host cells, which led to the name “Arena” (from the Latin “arena,” meaning sand).

LASV is classified as a Biosafety Level 4 (BSL-4) pathogen, the highest level of biocontainment, because it is highly infectious and can cause life-threatening disease for which no licensed vaccine currently exists. The virus is genetically diverse, with several different strains circulating across West Africa, making it a challenging target for diagnostic tests and vaccine developers.

Unlike some viruses that kill their hosts quickly, Lassa virus has a complex relationship with its natural reservoir, allowing it to persist in the environment for long periods.

How Lassa Virus Spreads: The Role of the Mastomys Rat

The transmission of Lassa virus is fundamentally linked to the ecology of West Africa. The virus is a zoonotic disease, meaning it jumps from animals to humans.

The Primary Vector: The Multimammate Rat

The natural reservoir for Lassa virus is the Mastomys natalensis rat, commonly known as the “multimammate rat.” These rodents are ubiquitous across sub-Saharan Africa. They are highly fertile and often live in close proximity to humans, nesting in houses, food stores, and agricultural fields.

The rats do not become ill from the virus; instead, they carry it for life and shed it in their:

• Urine
• Droppings (Feces)
• Saliva

Primary Human Infection

Humans typically become infected through “spillover” events:

1. Ingestion: Consuming food or water contaminated with rat urine or droppings.
2. Inhalation: Breathing in “aerosolized” particles of dried rat urine or droppings, which can happen while sweeping a dusty home.
3. Direct Contact: Touching contaminated surfaces and then touching the eyes, nose, or mouth.
4. Consumption of Rodents: In some regions, Mastomys rats are caught and eaten as a source of protein. Handling and preparing the meat can lead to direct infection.

Human-to-Human Transmission

While the majority of cases come from rats, Lassa virus can spread between people. This usually occurs in healthcare settings (nosocomial transmission) or within households when people come into direct contact with the blood, vomit, or feces of an infected person. Unlike the flu, it is not considered to be efficiently spread through casual respiratory contact, but it is highly dangerous in a clinical setting without proper personal protective equipment (PPE).

How the Body Responds: Affected Systems and Pathophysiology

Lassa virus is a systemic infection that primarily targets the vascular system and the immune response.

Suppressing the Immune System

Upon entering the body, LASV infects dendritic cells and macrophages. Similar to Ebola, Lassa virus is an expert at “immune evasion.” It blocks the production of Type I Interferons, which are the body’s primary antiviral signals. This allows the virus to replicate to massive levels before the immune system even realizes it is under attack.

The Vascular System and Edema

As the infection progresses, the virus causes generalized vascular damage. The blood vessels become “leaky,” leading to edema (swelling) in various parts of the body. This is particularly dangerous when it occurs in the lungs (pulmonary edema) or around the heart (pericardial effusion).

Liver and Multi-Organ Failure

The liver is a major target for LASV. The virus causes necrosis (cell death) in liver tissue, which disrupts the body’s ability to regulate metabolic functions and blood clotting. In severe cases, this leads to a “multi-organ failure” syndrome involving the kidneys and the gastrointestinal tract.

Recognizing the Signs: Symptoms of Lassa Fever

One of the greatest challenges with Lassa Fever is that its symptoms are incredibly varied. Approximately 80% of infections are mild or asymptomatic. However, for the remaining 20%, the disease is severe.

Early Phase (Days 1–7)

The onset is typically gradual, starting with non-specific symptoms:

• Low-grade fever and general weakness.
• Malaise and headache.
• Sore throat (often with white patches on the tonsils).
• Muscle pain and chest pain.

Severe Phase (Days 7–14)

If the disease progresses, more alarming signs appear:

• Swelling of the face and neck.
• Fluid in the lungs, causing respiratory distress.
• Persistent vomiting and diarrhea.
• Hemorrhage: Bleeding from the mouth, nose, vagina, or gastrointestinal tract. (Note: Despite being a “hemorrhagic fever,” visible bleeding occurs in less than 30% of severe cases).
• Encephalopathy (brain dysfunction), which can lead to seizures or coma.

Neurological Impact: The Link to Deafness

A unique and devastating complication of Lassa Fever is Sensorineural Hearing Loss (SNHL).

Approximately one-third (25–30%) of all Lassa Fever patients—even those with very mild or asymptomatic cases—experience sudden deafness. In many cases, this hearing loss is permanent. It can affect one or both ears.

The exact cause is still being studied, but it is believed to be an immunomediated response. The body’s own immune system, in its attempt to clear the virus, inadvertently damages the auditory nerve or the delicate structures of the inner ear. This makes Lassa Fever the leading cause of acquired deafness in West Africa.

Assessing the Danger: Mortality Rates and Risk Factors

The mortality rate for Lassa Fever varies significantly depending on the clinical setting:

• General Population: The overall case fatality rate (CFR) is approximately 1%.
• Hospitalized Patients: For those with severe symptoms requiring hospitalization, the CFR can jump to 15% to 20%.
• Pregnancy: Lassa Fever is particularly lethal for pregnant women. In the third trimester, the risk of maternal death and fetal loss is over 80%. The virus has a specific affinity for the placenta.

Death usually occurs within 14 days of symptom onset, typically due to multi-organ failure, severe drop in blood pressure (shock), or secondary bacterial infections.

Current Treatment: The Role of Ribavirin

As of 2026, there is no “cure” for Lassa Fever, but there is a standard antiviral treatment that can save lives if administered early.

Ribavirin

Ribavirin is an antiviral drug that has been used for decades to treat Lassa Fever. It is most effective when given intravenously within the first six days of symptom onset. Studies have shown that early treatment with Ribavirin can reduce the risk of death by up to 90% in severe cases.

However, Ribavirin is not a perfect drug. It can cause side effects like hemolytic anemia (the breakdown of red blood cells) and is generally not effective if the patient has already reached the stage of organ failure or shock.

Supportive Therapy

Beyond antivirals, “supportive care” is the backbone of survival:

• Maintaining fluid and electrolyte balance via IV.
• Oxygen therapy for respiratory distress.
• Dialysis for kidney failure.
• Blood transfusions if severe hemorrhage occurs.

The Race for a Lassa Vaccine

Currently, there is no licensed vaccine for Lassa Fever, but the search for one is a top priority for the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine Candidates in Progress

Several vaccines are in Phase I and Phase II human trials:

1. IAVI (rVSV-LASV): Using the same “viral vector” platform as the successful Ebola vaccine. It has shown great promise in animal models.
2. DNA and mRNA Vaccines: Newer technologies are being used to target the glycoprotein of the Lassa virus to induce a strong antibody response.
3. Live-Attenuated Vaccines: Research is ongoing to create a “weakened” version of the virus that provides lifelong immunity without causing disease.

The goal is to provide a vaccine that can be used routinely in endemic areas or deployed rapidly during seasonal “peaks” of rat activity.

Prevention and Control: Breaking the Rat-Human Chain

Prevention of Lassa Fever is largely a matter of “rodent control” and environmental hygiene.

1. Food Storage: Storing grains and other food in rodent-proof containers (metal or heavy plastic).
2. Home Hygiene: Keeping houses clean to avoid attracting rats. Sealing holes and cracks in walls and floors.
3. Safe Food Preparation: Avoiding the consumption of rats and ensuring all food is thoroughly cooked.
4. Health Care Safety: Implementing strict “Universal Precautions” in hospitals (gloves, masks, gowns) to prevent the spread from patient to nurse.

Conclusion: A Persistent Challenge

Lassa Fever is a disease of poverty and ecology. As long as the Mastomys rat thrives in human settlements and diagnostic tools remain out of reach for rural clinics, the virus will continue to claim lives. However, with the advancement of Ribavirin protocols and the promising horizon of a preventative vaccine, there is hope that Lassa Fever will one day be a manageable footnote in medical history rather than a yearly tragedy.

The key to fighting Lassa virus lies in awareness. Recognizing the symptoms early and understanding the importance of rodent-proofing our environments are the first steps in silencing this silent killer.

Frequently Asked Questions